That's what happens when a stock trades on R&D and not financials. ART trials starting this year, patent protected. Innovative superior technology , rock solid , billion dollar revenues expected. ART has been put on priority pps will follow now back to dollar land. $$$$$$$$$$$
Thanks for pointing out the R&D pps for ART opiods. Those suckers should have waited till now to get in. $22/ share is reasonable when ART opiods are launched and required by the FDA and Congress. Competitors are far and few. $22/ share did not include the 20 FDA approved products and did not include Elites 9.99% ownership in one of the largest generic co.s in the USofA, NOVELL LABS.
Yes $22/share. Saint Jerry remembers those $22/share days too. I agree it will be hysterically funny. I will be laughing all the way to the bank. LOL LOL $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$